Stopping GLP-1 drugs, such as Ozempic and Wegovy, has been linked to weight regain. The extent and implications of this weight regain are being studied, with some research suggesting that cardiovascular benefits may also be lost and that restarting the drugs may reduce their effectiveness. The amount of weight regained varies, with one study finding that patients retain about a quarter of their initial weight loss.